Phase III clinical trial - Appareil urinaire
Ouvert depuis le: 12.05.2023
A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)
Description de l'essai
This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact.